ANGLE PLC (AIM:AGL, OTCQX:ANPCY) chief executive Andrew Newland joins Proactive's Katie after landing a follow-on contract with a large client worth US$1.2mln for its new pharma services division.
This business offers a "completely new approach" for pharmaceutical companies to assess the results of drug drials in cancer patients using Angle's Parsortix system.
Newland explains how the system works and compares it to the current industry methods and the significance of how long it took the customer to sign up to the follow-up contract.